Researchers at the University of Louisville School of Medicine are using breath analysis to detect the presence of lung cancer.
Preliminary data indicate that this promising noninvasive tool offers the sensitivity of PET scanning, and has almost twice the specificity of PET for distinguishing patients with benign lung disease from those with early stage cancer. Michael Bousamra II, MD, Associate Professor, Department of Cardiovascular and Thoracic Surgery, is presenting the results of the study at the AATS 2014 Conference on April 29, 2014.
A reliable, noninvasive diagnostic method imposes less physical and financial burden on patients who actually have no significant disease, while rapid and accurate diagnosis expedites treatment for patients who truly have lung cancer.
The team believes that while the breath test would not replace CT as a primary screening tool, it would be particularly helpful in conjunction with a positive CT scan result. “This breath analysis method presents the potential for a cheaper and more reliable diagnostic option for patients found to have bulky disease on a CT scan. If the breath analysis is negative, the patient may, in some instances, be followed with repeated exams without necessitating a biopsy. But a positive breath analysis would indicate that the patient may proceed to definitive biopsy, thus expediting treatment,” says Dr. Bousamra.
Investigators used specially coated silicon microchips to collect breath samples from 88 healthy controls, 107 patients with lung cancer, 40 individuals with benign pulmonary disease, and 7 with metastatic lung cancer.
Previous work had pinpointed four specific substances, known as carbonyl compounds, in breath samples as “elevated cancer markers” (ECMs) that distinguish patients with lung cancer from those with benign disease. The carbonyl compounds found in the breath are thought to reflect chemical reactions occurring in malignant lung tumors. In this study, the authors compared the findings from the breath analyses to the results from PET scans.
The investigators found that the sensitivity and specificity of breath analysis depended upon how many of the ECMs were elevated. For example, having 3 or 4 ECMs was diagnostic of lung cancer in 95% of those with this result. The majority of patients with benign pulmonary disease had either 0 or 1 ECM, while those with Stage IV cancer were most likely to have 3 or 4. The number of ECMs could be used to differentiate benign disease from both early and advanced stage lung cancer. Interestingly, 3 of the 4 elevated markers returned to normal levels after cancer resection.
When it comes to differentiating early stage lung cancer from benign pulmonary disease, breath analysis and PET scanning had similar sensitivities (82.8% and 90.3%, respectively). However, breath analysis had a much higher specificity than PET (75% vs. 38.7%, respectively) for distinguishing benign disease, which means that it was much more accurate at identifying those who did not have cancer. This would be an important feature for patients with benign disease, since having a breath analysis rather than PET scan could mean avoiding an unnecessary invasive biopsy procedure later on.
The Latest on: Detect Early Lung Cancer
via Google News
The Latest on: Detect Early Lung Cancer
- New Drug Approved for Early Lung Canceron April 15, 2021 at 10:01 am
In China, AstraZeneca’s drug Tagrisso has been approved for early stage lung cancer treatment. Lung cancer is the leading cause of cancer death among both men and women.
- LifePoint to launch tech-powered program for early disease detectionon April 14, 2021 at 2:02 pm
The Healthy Person Program aims to provide timely notification of findings to providers and patients and support earlier detection of several diseases. The program builds on LifePoint and Eon's ...
- AstraZeneca: Tagrisso approved in China for the adjuvant treatment of patients with early-stage EGFR-mutated lung canceron April 14, 2021 at 1:00 am
SvD Näringsliv - nyheter inom ekonomi och näringsliv, aktier och börs. Bevakning av internationella affärer och marknader. Motor- och IT-nyheter.
- New lung cancer screening guidelines could save liveson April 13, 2021 at 3:02 am
More people will have access to potentially life-saving lung cancer screening exams with the introduction of new guidelines from the U.S. Preventive Services Task Force (USPSTF) that reduce both the ...
- Advocacy group underscores importance of early breast cancer detectionon April 12, 2021 at 7:07 pm
Advocacy group ICanServe reminded women of the importance of early breast cancer detection. In 2020, breast cancer became the number one cancer in the world, overtaking lung cancer. ICanServe, ...
- CT Lung Cancer Screenings at Trinitas Saves Liveson April 9, 2021 at 7:19 am
Trinitas Regional Medical Center offers a screening program to help identify lung cancer in its early stages. The low-dose, non-invasive CT scan takes about 30 seconds to complete before the test is ...
- Liquid biopsy maker Nucleix rakes in $55M to develop blood tests to detect lung cancer earlyon April 8, 2021 at 7:20 am
It’s full steam ahead for Nucleix’s blood test for lung cancer detection, thanks to an influx of cash in the Israeli company’s latest round of funding. The liquid biopsy maker closed its ...
- 'I was speechless': Lung cancer survivor champions screening method Vanderbilt helped expandon April 7, 2021 at 8:38 am
Cheryl Livingston beat cancer twice. Now, she considers herself a "poster child" for lung screening geared toward early detection.
- Lung cancer screening guidelines were recently expanded. Here's why they could be life-savingon April 7, 2021 at 8:38 am
"Cancer doesn't wait for anybody," Vanderbilt thoracic surgeon Erin Gillaspie said. "Screening is life-saving." ...
- Nucleix Nabs $55M For Lung Cancer Detectionon April 7, 2021 at 7:25 am
San Diego-based Nucleix, a startup which is developing liquid biopsy technology for early detection of lung cancer, has raised $55M in a funding round, the company announced this morning. The company ...
via Bing News